Iovance Biotherapeutics
IOVA
12.92
-0.05
-0.35%
Iovance Biotherapeutics
US · IOVA
#1864 by market cap
Listed 1970
12.92
-0.05
-0.35%
Live - 5344 symbols - heartbeat 536s ago
· 2026-10-08 07:39
Pre-market
12.81
-0.81%
After-hours
12.88
-0.27%
Overnight
12.94
+0.19%
- Market cap
- 5.85B
- P/E (TTM)i
- -18.72
- P/Bi
- 7.95
- EPSi
- -1.09
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on IOVA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 11.35, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +60.60% YoY
Margins
- Gross margin
- 34.28%
- Operating margin
- -151.12%
- Net margin
- -148.38%
Key ratios & quality
- Altman Z-Scorei
- 11.35
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 1.19M | 164.07M | 263.50M |
| Gross profit | -- | -- | -- | 0 | 0 | 156.00K | 70.82M | 90.32M |
| Selling & admin expenses | 28.43M | 40.85M | 60.21M | 83.66M | 104.10M | 106.10M | 152.27M | 152.32M |
| Research & development | 99.83M | 166.02M | 201.73M | 259.04M | 294.78M | 333.19M | 276.23M | 300.27M |
| Operating profit | -128.26M | -206.87M | -261.94M | -342.70M | -398.88M | -460.56M | -395.28M | -398.21M |
| Pretax profit | -123.58M | -197.56M | -259.58M | -342.25M | -395.89M | -447.52M | -375.01M | -393.05M |
| Tax | -- | -- | -- | 0 | 0 | -3.48M | -2.83M | -2.07M |
| Net profit | -123.58M | -197.56M | -259.58M | -342.25M | -395.89M | -444.04M | -372.18M | -390.98M |
| Basic EPS | -1 | -2 | -2 | -2 | -2 | -2 | -1 | -1 |
| Diluted EPS | -1.27 | -1.59 | -1.88 | -2.23 | -2.49 | -1.89 | -1.28 | -1.09 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 49.32M | 59.95M | 67.46M | 86.77M | 71.43M | 99.31M |
| Gross profit | 6.61M | 11.07M | 28.98M | 43.66M | 28.93M | 55.72M |
| Selling & admin expenses | 43.80M | 37.57M | 34.56M | 36.40M | 38.95M | 39.27M |
| Research & development | 75.97M | 77.93M | 75.17M | 71.20M | 62.49M | 58.85M |
| Operating profit | -121.22M | -113.77M | -89.76M | -73.46M | -81.04M | -51.91M |
| Pretax profit | -118.00M | -109.67M | -93.66M | -71.72M | -79.71M | -48.69M |
| Tax | -1.84M | 1.99M | -2.41M | 184.00K | -665.00K | -1.37M |
| Net profit | -116.16M | -111.66M | -91.25M | -71.90M | -79.05M | -47.32M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.36 | -0.33 | -0.25 | -0.18 | -0.19 | -0.11 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 475.37M | 316.49M | 636.10M | 507.96M | 479.12M | 307.85M | 457.02M | 442.69M |
| Cash & ST investments | 468.52M | 307.08M | 629.44M | 504.41M | 471.85M | 279.87M | 323.78M | 296.98M |
| Inventory | -- | -- | -- | -- | 0 | 10.37M | 51.52M | 51.68M |
| Total assets | 480.82M | 344.66M | 768.46M | 777.33M | 663.98M | 780.35M | 910.43M | 913.17M |
| Total current liabilities | 14.40M | 39.08M | 54.87M | 89.20M | 91.49M | 110.31M | 122.34M | 138.36M |
| Short-term debt | -- | 7.25M | 6.28M | 5.06M | 12.59M | 7.78M | 12.90M | 5.04M |
| Long-term debt | -- | -- | -- | 1.00M | 1.00M | 1.00M | 1.00M | -- |
| Total liabilities | 14,628,000.00 | 45,684,000.00 | 111,960,000.00 | 155,674,000.00 | 164,344,000.00 | 195,738,000.00 | 200,021,000.00 | 214,587,000.00 |
| Total equity | 466.19M | 298.97M | 656.50M | 621.66M | 499.64M | 584.61M | 710.41M | 698.58M |
| Retained earnings | -372.76M | -570.61M | -830.19M | -1.17B | -1.57B | -2.01B | -2.38B | -2.78B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 512.65M | 422.50M | 429.09M | 442.69M | 466.50M | 464.26M |
| Cash & ST investments | 359.71M | 301.18M | 300.80M | 296.98M | 313.44M | 110.77M |
| Inventory | 65.55M | 49.83M | 51.71M | 51.68M | 58.38M | 55.59M |
| Total assets | 966.74M | 907.44M | 904.95M | 913.17M | 925.67M | 915.53M |
| Total current liabilities | 122.69M | 129.16M | 125.79M | 138.36M | 129.42M | 106.85M |
| Short-term debt | 9.50M | 8.07M | 7.28M | 5.04M | 3.90M | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 198,875,000.00 | 208,949,000.00 | 202,661,000.00 | 214,587,000.00 | 203,911,000.00 | 179,486,000.00 |
| Total equity | 767.87M | 698.49M | 702.29M | 698.58M | 721.75M | 736.05M |
| Retained earnings | -2.50B | -2.61B | -2.70B | -2.78B | -2.85B | -2.90B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -101.25M | -158.89M | -205.13M | -227.94M | -292.76M | -361.82M | -352.98M | -302.41M |
| Depreciation & amortization | 956.00K | 8.12M | 8.71M | 13.98M | 21.14M | 33.13M | 48.07M | 47.32M |
| Free cash flow | -102.45M | -165.81M | -251.93M | -265.52M | -313.18M | -384.11M | -364.05M | -336.24M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 398.82M | 0 | 567.04M | 203.16M | 189.50M | 463.28M | 397.30M | 306.31M |
| Ending cash balance | 82.15M | 19.42M | 72.85M | 84.31M | 238.16M | 181.32M | 122.05M | 169.06M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -103.69M | -67.45M | -78.70M | -52.57M | -72.07M | -60.84M |
| Depreciation & amortization | 10.94M | 12.23M | 11.52M | 12.64M | 10.42M | 10.40M |
| Free cash flow | -109.91M | -74.91M | -89.55M | -61.89M | -78.68M | -66.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 148.94M | 13.07M | 88.52M | 55.78M | 98.51M | 49.57M |
| Ending cash balance | 178.05M | 138.41M | 164.10M | 169.06M | 202.50M | 116.77M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -40.41 | -51.64 | -54.34 | -53.55 | -70.61 | -81.91 | -57.48 | -55.50 |
| ROA %i | -38.85 | -47.86 | -46.64 | -44.28 | -54.94 | -61.49 | -44.02 | -42.88 |
| ROIC %i | -40.41 | -50.13 | -50.97 | -48.91 | -62.41 | -73.38 | -54.90 | -52.91 |
| 5-year avg ROE %i | -50.12 | -52.74 | -56.18 | -51.78 | -54.11 | -62.41 | -63.58 | -63.81 |
| EBIT margin %i | -- | -- | -- | -- | -- | -38,734.99 | -240.92 | -151.12 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 33.02 | 8.10 | 11.59 | 5.69 | 5.24 | 2.79 | 3.74 | 3.20 |
| Quick ratioi | 32.54 | 7.86 | 11.47 | 5.65 | 5.16 | 2.54 | 3.21 | 2.74 |
| Debt / assetsi | 0.00 | 3.34 | 6.72 | 9.20 | 12.87 | 9.72 | 6.40 | 5.41 |
| LT debt / equityi | -- | 1.42 | 6.91 | 10.69 | 14.58 | 11.65 | 6.39 | 6.36 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -51.85 | -53.16 | -53.89 | -55.50 | -47.51 | -40.74 |
| ROA %i | -40.88 | -41.66 | -41.94 | -42.88 | -37.40 | -31.76 |
| ROIC %i | -49.86 | -50.75 | -51.74 | -52.91 | -45.54 | -39.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -187.50 | -170.02 | -164.25 | -151.12 | -125.36 | -91.14 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.18 | 3.27 | 3.41 | 3.20 | 3.60 | 4.35 |
| Quick ratioi | 3.51 | 2.80 | 2.92 | 2.74 | 3.05 | 1.04 |
| Debt / assetsi | 5.56 | 5.86 | 5.80 | 5.41 | 5.16 | 5.02 |
| LT debt / equityi | 5.76 | 6.46 | 6.44 | 6.36 | 6.08 | 5.99 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Amtagvi® is the largest reported line at 91.35% of revenue, across 2 reported segments.
- The next-largest line, Proleukin®, is a distant second at 8.65% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Amtagvi®91.35%
Proleukin®8.65%
Quote time 2026-10-08 07:39:53 · For reference only, not investment advice and not tailored to your situation.